{"entity":{"id":"trop2-car-il15-cord-blood-nk","kind":"drug","name":"TROP2 CAR/IL-15 cord-blood NK cells","aka":[],"tldr":"These experimental immune cells are designed to recognize TROP2 on cancer cells. Early trials are studying their safety and activity.","summary":"AACR 2026 abstract CT294 describes the TROPIKANA phase 1 protocol in advanced TROP2-positive solid tumors, with lymphodepletion and engineered cord-blood NK cells. It reports trial design and first treatment in January 2024, not a clinical response or survival result. NCT06066424 is recruiting with 54 planned participants. A separate colorectal minimal-residual-disease study, NCT06358430, combines this cell platform with cetuximab; it does not establish postoperative TNBC benefit.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1158/1538-7445.am2026-ct294"},{"label":"Publisher abstract","url":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps275"},{"label":"ClinicalTrials.gov NCT06066424","url":"https://clinicaltrials.gov/study/NCT06066424"},{"label":"ClinicalTrials.gov NCT06358430","url":"https://clinicaltrials.gov/study/NCT06358430"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-nk-macrophage"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06066424","nct06358430"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"CAR-NK cell therapy","mechanism":"Cord-blood natural killer cells engineered with a TROP2 CAR, IL-15 to support persistence, and an inducible caspase-9 safety switch.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/trop2-car-il15-cord-blood-nk/","neighbours":{"technology":[{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct06358430","kind":"trial","name":"Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)","route":"/trials/nct06358430/"},{"id":"nct06066424","kind":"trial","name":"Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)","route":"/trials/nct06066424/"}]}}